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Background: Effective and safe management of oral anticoagulant treatment (OAT) requires a high level of patient
knowledge and adherence. The aim of this study was to assess patient knowledge about OAT and factors
associated with patient knowledge.
Methods: This is a baseline survey of a cluster-randomized controlled trial in 22 general practices with an educational
intervention for patients or their caregivers. We assessed knowledge about general information on OAT and key facts
regarding nutrition, drug-interactions and other safety precautions of 345 patients at baseline.
Results: Participants rated their knowledge about OAT as excellent to good (56%), moderate (36%) or poor (8%).
However, there was a discrepancy between self-rated knowledge and evaluated actual knowledge and we observed
serious knowledge gaps. Half of the participants (49%) were unaware of dietary recommendations. The majority (80%)
did not know which non-prescription analgesic is the safest and 73% indicated they would not inform pharmacists
about OAT. Many participants (35-75%) would not recognize important emergency situations. After adjustment in a
multivariate analysis, older age and less than 10 years education remained significantly associated with lower overall
score, but not with self-rated knowledge.
Conclusions: Patients have relevant knowledge gaps, potentially affecting safe and effective OAT. There is a need to
assess patient knowledge and for structured education programs.
Trial registration: Deutsches Register Klinischer Studien (German Clinical Trials Register): DRKS00000586.
Universal Trial Number (UTN U1111-1118-3464).Background
Thrombosis and atrial fibrillation are the major indications
for oral anticoagulation therapy (OAT). Due to an increase
in aging population, the number of adults with atrial fibril-
lation will increase considerably. Consequently, a global in-
crease in the number of patients requiring OAT is expected
over the next decades [1]. The effectiveness of OAT to re-
duce risk of stroke or recurrent thrombosis has been
proven and OAT is recommended in guidelines [2,3]. Fre-
quently used drugs for OAT are warfarin, phenprocoumon* Correspondence: jchenot@uni-greifswald.de
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adherence and a low level of patient knowledge about OAT
are the primary causes for complications [4-6]. OAT thus
requires regular monitoring of the international normalized
ratio (INR) and dose adjustments, as well as a high level of
patient knowledge and adherence to recommendations on
nutrition, medication and recognition of critical situations.
Bleeding complications occur in 0.3 to 0.4% of all patients
with OAT every year, but risk estimates vary widely [7,8].
While educational programs, self-monitoring and self-
management of OAT have been established this is not suit-
able for many patients [9]. Standardized education pro-
grams for patients without self-monitoring are lacking in
many countries [4,6]. The best strategy to educate patients
about oral anticoagulation has not been determined yetLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Recruitment flow.
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jority of patients with OAT, there are no coagulation clinics.
Some general practitioners use self-written patient informa-
tion brochures to inform patients about OAT. Content and
quality of these brochures is heterogeneous and sometimes
inaccurate. It is known that information brochures on OAT
require reading levels, exceeding the capacity of many pa-
tients [12].
The aim of this study was to assess patients’ know-
ledge about OAT and factors associated with patient
knowledge.
Methods
This is a baseline survey within a cluster-randomized
controlled study conducted in 22 general practices in
Germany. The Ethics Committee of the medical school
of the University of Göttingen approved this study. A
detailed study protocol has been published [13].
Recruitment of practices and patients
A total of 22 general practices out of 85 practices agreed
to participate in the study (2 practices did not exist any-
more, 3 were put on a waiting list). Addresses were ob-
tained from the local Association of Statutory Health
Insurance Physicians (Kassenärztliche Vereinigung).
The GPs (n = 32) were on average 12.7 years in practice
(SD ± 6.9), 49 years old (SD ± 6) (national average
50.4 years) and 52% of them were female (national
average 38%). A total of 18 (80%) practices were run by
a single GP. The study was conducted in two medium
size university cities (5 practices) and surrounding small
towns (10 practices) and rural areas (7 practices), thus be-
ing representative for most parts of Germany except for
large cities. All, but one of the practices were part of the
educational network of the university.
The 986 patients receiving OAT with phenprocoumon,
which is the drug most widely used in Germany for OAT,
were identified by searching the GPs’ electronic medical re-
cords for the laboratory billing code for INR measurement.
The inclusion criteria were age (≥18 years), receiving OAT
and willingness to participate in the study. For patients not
managing OAT themselves, their caregivers were invited
to participate as a substitute but will not be reported
here. Exclusion criteria were: inability to give informed
consent, management of anticoagulation with self-
monitoring (PSM), nursing home residency, insufficient
command of German and patients only seen in cross
coverage. New oral anticoagulation agents like dabiga-
tran and rivaroxaban had entered the European market
in August and December 2011, respectively, and were
therefore rarely used during the time of patient recruit-
ment in 2010–11. A total of 577 patients, representing
59% of all potentially eligible patients, were contacted
by the practice nurse in order to fix an appointment forINR control. Finally, 345 patients were included in the
study. The recruitment is shown in Figure 1.Data collection
Demographic data of the participants and patient
knowledge about OAT were collected at baseline with
a self-developed questionnaire based on models from
the literature [14,15]. We chose to use a self-developed
questionnaire, because we felt that existing instruments
were not comprehensive enough or were not sufficiently
adaptable to the specific situation in Germany. The ques-
tionnaire evaluated patient knowledge about general infor-
mation on OAT, and relevant facts regarding nutrition,
drug-interactions and other safety precautions such as
recognition of complications and informing health care
professionals about OAT. Questions were based mainly
on relevant national guidelines and expert knowledge
[3,10,16]. The questionnaire was piloted previously
with 12 patients in a practice, which did not participate
in the trial using the think aloud technique [17] and
optimized accordingly to ensure comprehensibility.
An English version of the questionnaire is available
online [13]. Participants had to fill out the question-
naire themselves under supervision in the practice,
without any assistance. Patient names and other confi-
dential information were coded to make it difficult to
track individual patients. Informed consent and ques-
tionnaires were returned to the study center separately
by the practice.
Table 1 Socio-demographic and clinical characteristics
(n = 345)




Age (median/IQR***) 74 years
(68–78)
Education*
< 10 years education 253 (73%)
≥ 10 years education 92 (27%)
Indication for oral anticoagulation
according to the patient**
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Categorical data were summarized as frequencies and
percentages, quantitative variables as medians and inter-
quartile ranges (IQR). For the 13-item knowledge score,
all thirteen questions were weighted equally with one
point. The total-sum score ranges from 0 to 13, with
higher scores indicating greater knowledge.
For questions with multiple yes/no answers the one
point awarded to the question in total was divided across
all answers. Correct answers received twice the weight
of incorrect answers. Indicating “I don’t know” led to 0
points irrespective of which other correct or incorrect
answers were ticked. For instance, in question 12 the
first four answers were correct, the fifth answer was in-
correct, the sixth was “I don’t know”. The four correct
answers were weighted by 2/9 points each. The fifth an-
swer which was incorrect carried a weight of 1/9. “I
don’t know” carried no weight. For example ticking the
first four answers in question 12 gave the maximum
score of 1 point. Ticking the first five answers was
awarded 8/9 points. Ticking all six answers resulted in
no point at all.
To explore factors associated with the score we con-
ducted univariate and multiple regression analyses fitting
linear mixed effects models with age, gender, years of
education (dichotomized to “less” and “more or equal”
than 10 years), fear of bleeding, history of prior OAT
related complications, self-rated knowledge as fixed
effects, and practice as random effect. The latter
accounted for possible correlations between patients
from the same practice and thereby adjusted for pos-
sible cluster effects. SAS 9.3 (SAS, Cary, NC) was used
for statistical analysis. P-values were not adjusted for
multiplicity and p-values smaller than 0.05 are referred
to as statistically significant.Atrial fibrillation 239 (70%)
Deep vein thrombosis 70 (21%)
Pulmonary embolism 35 (10%)
Artificial heart valve 22 (6%)
Unknown to the patient 16 (5%)
Missing 5 (1%)
OAT related complication in history 29 (9%)






Afraid of complications 182 (54%)
* < 10 years corresponds to lowest educational level, more than 10 years to a
medium to high educational level.
**Multiple indications for oral anticoagulation therapy (OAT) possible.
*** IQR = interquartile range.Results
Participants’ characteristics
Of the 345 patients, roughly half (163; 47%) were
women. The median age of the participants was 74 years
(IQR: 68–78) and 253 participants (73%) had an educa-
tional level of less than 10 years of school education
(Figure 1). The most common indication for OAT was
atrial fibrillation (70%). Patients receiving oral anticoagu-
lants for recurrent thrombosis or pulmonary embolism
were younger than those with atrial fibrillation: 75 years
(IQR 69–79) versus 72 (IQR 63–78) years. A total of 9%
of the participants reported previous complications re-
lated to OAT. More than half (54%) of all participants
were afraid of complications related to OAT (Table 1).
To assess for presence of selection bias we compared
age and gender between patients finally enrolled in the
study, patients declining to participate and patients whowere contacted by the practice. There were no statisti-
cally significant differences (results not shown).
Patient knowledge
Most participants knew their indication for OAT (95%)
and how frequently their coagulation status should be
controlled (82%), but in most other areas we observed
substantial knowledge gaps (Table 2). A total of 80% of
participants did not know which non-prescription analgesic
is the safest option for them and 17% indicated they would
take non-steroidal anti-inflammatory drugs (NSAIDs). 68%
of participants did not know that they had to follow a spe-
cific diet. Women had a slightly better knowledge on ques-
tions regarding nutrition. Most of the participants were
not aware that gastroenteritis, fasting, or non-
prescription medicines, could affect the effectiveness
of OAT (82%, 86% and 79%, respectively). Many partic-
ipants were not aware of complications of over- and
under-dosing. For example, paresis and melaena were
not considered an emergency by 74% and 60% of the
Table 2 Answers to questionnaire assessing knowledge on oral anticoagulation therapy (n = 345)
# Correct answer Correct n (%) Incorrect* n (%) Score
1 Indication for OAT known Individual 329 (95%) 16 (5%) 1
2 Awareness of risk treated with OAT Individual 278 (81%) 67 (19%) 1
3 Duration of treatment known Individual 249 (72%) 96 (28%) 1
4 Frequency of controls known Individual 278 (81%) 67 (19%) 1
5 Awareness of target INR range Individual 158 (46%) 187 (54%) 1
6 Need to follow a specific diet
Overall 107 (31%) 238 (69%) 1
• Consuming large amounts of salad and vegetables No 11 (3%) 0
• Avoid salad and vegetables No 57 (17%) 0
• Regular diet of salad and vegetables Yes 107 (31%) 1
• Do not know No 170 (49%) 0
7 Vitamin K content of some foods
Overall 1
• Cabbage Yes 245 (71%) 100 (29%) 1/8
• Potatoes No 283 (82%) 62 (18%) 1/8
• Apples No 284 (82%) 61 (18%) 1/8
• Green salad Yes 155 (45%) 190 (55%) 1/8
• Tomato extract No 260 (75%) 85 (25%) 1/8
• Spinach No 164 (48%) 181 (52%) 1/8
• Onion Yes 37 (11%) 308 (89%) 1/8
• Zucchini No 268 (78%) 77 (22%) 1/8
8 Management of missed medication dose n.a. 46 (13%) 299 (87%) 1
9 Awareness that there are no symptoms of underdosing n.a. 194 (56%) 151 (44%) 1
10 Safest over the counter pain medication
Overall 68 (20%) 277 (80%) 1
• Paracetamol/acetaminophen Yes 68 (20%) 1
• Aspirin (acetylsalicylic acid) No 21 (6%)
• Other non-steroidal anti-inflammatory drugs No 37 (11%)
• Do not know No 219 (63%)
11 Interaction with OAT
Overall 1
• Regular exercise No 264 (77%) 81 (23%) 1/8
• Gastroenteritis Yes 60 (17%) 285 (83%) 1/8
• Fever Yes 16 (5%) 328 (95%) 1/8
• Coffee No 327 (95%) 18 (5%) 1/8
• Ginkgo biloba Yes 16 (5%) 329(95%) 1/8
• Non-prescription drugs Yes 71 (21%) 274 (79%) 1/8
• Moderate intake of alcohol No 272 (79%) 73 (21%) 1/8
• Fasting/weight reduction diet Yes 48 (14%) 297 (86%) 1/8
12 Recognition of emergency situations
Overall 1
• Painful swelling with or without skin discoloration Yes 95 (28%) 250 (72%) 1/5
• Sudden speech disorder Yes 169 (49%) 176 (51%) 1/5
• Black stool (melaena) Yes 133 (39%) 212 (61%) 1/5
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Table 2 Answers to questionnaire assessing knowledge on oral anticoagulation therapy (n = 345) (Continued)
• Arm weakness (also temporarily) Yes 85 (25%) 260 (75%) 1/5
• Every cut or injury with bleeding Yes 224 (65%) 121 (35%) 1/5
13 Important situation to inform others about OAT
Overall 1
• Dental visits Yes 312 (90%) 33 (10%) 1/5
• Pharmacist Yes 93 (27%) 252 (73%) 1/5
• Before injections Yes 156 (45%) 189 (55%) 1/5
• Any new prescription medication Yes 191 (55%) 154 (45%) 1/5
• Before invasive medical procedures Yes 305 (88%) 40 (12%) 1/5
Maximum score 13
OAT oral anticoagulation therapy, n.a. non applicable. *non-response was treated as incorrect answer.
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(88%) indicated they would inform health professionals
about their OAT before undergoing planned invasive
medical procedures. However, 72% of the participants
would not inform their pharmacists about OAT.
Overall 13-item score and self-rated knowledge
Participants rated their knowledge about OAT as excellent
(9%), good (47%), moderate (36%) and poor (8%) (Table 1).Figure 2 Association of the 13-item knowledge score with age, gende
equal 10 years), fear of bleeding, history of prior OAT related complicThe median overall score was 6.8 (IQR 5.2-8.1). There was
a small statistically significant association between self-
rated knowledge and age below 65 years towards a higher
overall-score in univariate analysis. Patients who rated their
knowledge as excellent had a median score of 7.8 (IQR
6.6– 8.9) and those who rated their knowledge as poor of
merely 5.6 (IQR 3.8 – 6.6). In univariate analyses higher
education and lower age were statistically significant related
to higher score, but not gender, history of prior OATr, years of education (dichotomized to smaller, and larger or
ations and self-rated knowledge.
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differences for age and education remained associated
in multivariate analysis (Table 3). Age had a negative
coefficient of −0.044 with each year of age. The 21 pa-
tients who did not know why they were taking OAT
had on average 1.8 points less (p <0.001) on the overall
score disregarding this item.
There were additionally 22 caregivers participating as
substitutes for patients in this study (Figure 1). The data
on these substitutes has not been included in the general
analysis to avoid bias. Overall they achieved a better me-
dian score than patients. But the numbers of caring rela-
tives was too low for meaningful statistical inference.
Discussion
Summary of the main results
The results of our survey on patient knowledge show
relevant knowledge gaps affecting safe and effective
OAT. There was a discrepancy between self-rated know-
ledge and evaluated actual knowledge. Many participants
did not recognize symptoms of emergency situations
and had poor awareness of drug interactions, particularly
regarding over the counter medication (OTC) and other
factors influencing the effects of oral anticoagulants. The
overall results are unsatisfying and concerning given that a
low level of patient knowledge about OAT is the major
cause for bleeding complications [4-6]. Lower levels of edu-
cation, older age and unawareness about the indication for
OAT were associated with lower knowledge about OAT.
Meaning of the results and comparison with literature
More than half of the patients rated their knowledge on
OAT as good or excellent. Despite a correlation between
self-evaluation and overall score the actual knowledge wasTable 3 Factors associated with the 13-item knowledge score
Factor Effe
Age (in years) −0.0
Gender (women vs. men) −0.1
Education
< 10 years education vs. ≥ 10 years education −0.6
Self-rated knowledge
Good vs poor 2.47
Excellent vs poor 1.63
Moderate vs poor 1.24
history of OAT related complications none vs complications 0.04
Fear of bleeding
Fully agree vs disagree entirely −0.3
Agree vs disagree entirely 0.09
Do not agree vs disagree entirely 0.026
OAT oral anticoagulation therapy.overall low and poor in many safety relevant areas. This
confirms findings of many smaller studies [15,18-22].
The majority of patients in our survey knew why they
were receiving OAT. Not knowing the indication for
OAT was a predictor for poor knowledge. Therefore ask-
ing patients why they are taking OAT might be useful to
identify patients with an urgent need for instructions. A
Spanish study and an Italian study observed that the
time spent in the therapeutic range was lower in elderly
patients not aware of their indication for OAT [19,20].
This is in line with our finding that older age is associated
with a lower number of correct answers. This was also ob-
served by others [21,22]. Although one study found that
older age was not associated with an increased risk for
bleeding complications [8], others observed a higher inci-
dence of both bleeding and thromboembolic events with
advancing age [7]. Cognitive impairment in elderly patients
has been associated with inadequate INR control [23].
Only one third of the participants were aware that pa-
tients on OAT should follow a regular diet of salad and
vegetables to ensure steady vitamin K supply. It has been
shown that eating a diet high in vitamin K, reduces the
risk of INR measurements in the subtherapeutic range
[24]. A significant proportion (11%) was possibly misin-
formed and assumed that they should avoid vegetables.
Avoiding vegetables to minimize variation in vitamin K
intake is not compatible with a healthy diet, as recom-
mended by current guidelines [25]. This dietary restric-
tion is frequently perceived as a significant reduction in
quality of life by many patients [26].
We observed a low awareness of drugs affecting the
pharmacodynamics of OAT, particularly with OTC
medication and herbal medicines. Popular herbal med-
icines like ginkgo biloba extracts and St. John’s wortoforal anticoagulation therapy (n = 345)
Univariate Multivariate
ct (SE) p-value Effect (SE) p-value
54 (0.1) <0.01 −0.044 (0.01) <0.001
1 (0.23) 0.64 0.02 (0.23) 0.92
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aspirin and NSAIDs increase bleeding risk, when used
in combination with OAT [29]. Most participants did
not know which OTC analgesic is safe for patients with
OAT and even worse some indicated they would buy
aspirin or other OTC NSAIDs. Only 20% were aware
that paracetamol (acetaminophen) is considered the
safest OTC analgesic for patients on OAT with phen-
procoumon [30,31]. This lack of knowledge is
particularly worrisome since two thirds of the partici-
pants indicated they would not inform pharmacists
about concomitant use of OAT when purchasing OTC
medication. However, most participants would inform
dentists and physicians before undergoing invasive
medical procedures.
More than half of the participants did not recognize
emergency situations such as symptoms of stroke or
bleeding complications as an emergency situation in
which they should seek immediate medical attention.
Several studies have demonstrated that awareness of
symptoms of stroke and recognition of stroke as an
emergency in the general populations is low [31]. A
group of patients with increased risk of stroke should
have higher awareness in order to take appropriate ac-
tion, if needed.
Implications for practice
Patients who have already experienced complications re-
lated to OAT should be offered instructions or should
seek instructions themselves to avoid future complications.
However, no higher levels of knowledge were observed in
this patient group.
Overall the results of our survey are worrisome and call
for structured programs to ensure patient knowledge ne-
cessary for safe and effective OAT. It cannot be assumed
that one educational intervention is sufficient to maintain
necessary knowledge. Although we did not formally assess
previous educational activities on OAT, we are aware of the
fact that many patients in our sample had been taking OAT
for a number of years and had been exposed some form
of formal or informal education, regarding their ther-
apy. Therefore periodical reassessment might be neces-
sary. The best strategy for an education program about
oral anticoagulation has not been determined yet [10].
An Italian study evaluated the short-term effects of an
educational program that did not improve the time
spent in the therapeutic range in the short term [32].
In contrast, a French study could show that an educa-
tion program lowers the complication rate of patients
on OAT [33]. A systematic review on the effectiveness
of educational interventions to improve the proportion
of time spent in the therapeutic range was inconclusive
[11]. The included studies were too small to make in-
ferences on complications. Many questions about thebest strategy to educate anticoagulated patients remain
to be answered. However significant differences in
health care systems and the management of OAT will
most likely result in different solutions.
Strength and limitations
To our knowledge this is the largest study, assessing patient
knowledge about OAT in a representative sample of
primary care patients [11]. Previous studies on patient
knowledge were conducted in hospitals or with mostly
younger patients [22] often within the frame of patient self-
monitoring [9,34]. The results of these studies can therefore
not be generalized to the majority of elderly patients [9].
Studies assessing patient knowledge are prone to selection
bias. However, we have a high contact and participation
rate and comparison of age and gender did not show statis-
tically significant differences of contacted patients and
refusing patients compared to participants. We did not
inquire about previous education on OAT since there is
no generally established education program for OAT in
Germany [4]. Although we did not assess the duration of
OAT, we believe that the majority of patients included in
this study have been taking OAT for several years.
Conclusions
We demonstrate that patients in the general practice setting
have relevant knowledge gaps, potentially affecting safe and
effective OAT. GPs should be aware that most patients
overestimate their knowledge. There is a need to assess pa-
tient knowledge and for effective education program which
might need to be repeated periodically. Education programs
should focus on drug interactions with non-prescription
drugs, dietary advice and recognition of emergency situa-
tions. This need for education will persist even when
vitamin-K antagonist will be replaced with new drugs.
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